Table 5.
Clinical management practices of nephrotoxicity and ototoxicity symptoms of injectables in patients on MDR-TB treatment follow-up at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia
| Management practice & injectables involved in toxicity | Nephrotoxicity cases (N = 62) | Ototoxicity symptoms (N = 42) |
|---|---|---|
| Decreased frequency of capreomycin dose to 2x/week, or 3x/week | 6 | 1 |
| Withhold and discontinue capreomycin treatment | 28 | 2 |
| Discontinue, and then taper capreomycin treatment | 1 | 1 |
| Discontinue kanamycin treatment | 1 | |
| Tapering capreomycin dose from 1000 to 750 mg /day +3x/week | 2 | 1 |
| Stop injection for 15 days | 1 | |
| Close follow-up | 1 |